Proton pump inhibitor use and risk of developing Alzheimer's disease or vascular dementia

Date of Approval
Application Number
16_123
Technical Summary

The aim of this study is to explore the association between proton pump inhibitor (PPI) use and the risk of developing Alzheimer's disease (AD) or vascular dementia (VaD). We propose a case-control analysis using CPRD data between January 1998 and December 2015. The study population will consist of cases of well-defined incident AD or VaD within the study period, and a group of dementia-free control patients, matched to cases at a 1:1 ratio on age, sex, calendar time, general practice, and number of years of recorded history. We will quantify relative risk estimates (calculated as odds ratios) of developing AD or VaD in relation to duration and timing of previous PPI use (as the main exposure of interest). We will also analyse previous use of histamine-2 receptor antagonists (H2RAs), another group of acid-reducing drugs, as an indirect comparator. We will apply multivariable conditional logistic regression analyses to calculate odds ratios with 95% confidence intervals.

Health Outcomes to be Measured

Duration of PPI/H2RA use Timing of the last PPI/H2RA prescription

Collaborators

Christoph Meier - Chief Investigator - University of Basel
Patrick Imfeld - Corresponding Applicant - University of Basel
Michael Bodmer - Collaborator - University of Basel
Susan Jick - Collaborator - BCDSP - Boston Collaborative Drug Surveillance Program